Cambridge Healthtech Institute’s 4th Annual

Immunomodulatory Approaches

Harnessing the Immune Response and Overcoming Inhibitory Factors

18-19 March 2019

 

Research to date on CHI’s fourth annual Immunomodulatory Approaches reveals exciting progress on multiple fronts. After the initial excitement of checkpoint inhibitors, investigators are turning their attention to the mechanisms involved and to understanding and managing the non-responders. The multiple factors that interact in the tumour microenvironment including the cells involved and immunocytokines are major areas of interest. Moreover, investigators are coming up with clever and often complex ideas for enhancing efficacy and overcoming toxicity such as clever targeting and a focus on Fc engagement. Attendees will learn about the advances being made by the pioneers in this exciting field.

 

Coverage will include, but is not limited to:

 

  • Targeting immune checkpoint inhibitors: Modes of action and mechanisms of response; multiple checkpoint blockade; managing non-responders
  • Targeting Tregs, T effectors, NK cells and myeloid-derived suppressor cells
  • Immunocytokine approaches: Modes of action and means of overcoming toxicity
  • Enhancing safety and efficacy
  • Enhancing Fc receptor engagement: Means of manipulating Fc receptors to enhance the activity of checkpoint inhibitors and agonists; models to use; potential for combining with other approaches
  • Agonistic receptor engagement and immunostimulatory approaches: Choice of agonistic targets; approaches for stimulation of agonists; measures to overcome toxicity
  • Targeting the innate immune response - NK cells and myeloid cells: Roles of these cells in immune checkpoint regulation; challenges with target selection; preclinical models; assessment of efficacy; safety and tox concerns; potential for combining the targeting of these cells with other immune-modulatory approaches
  • The tumour microenvironment: FAP expression; targeting the stroma; factors that actively enable or actively inhibit
  • Benefits of bispecifics for immuno-oncology: Including next-generation bispecifics for redirected T cell killing
  • Emerging immuno-oncology targets: Unique approaches

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is 10 September 2018.

 

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:
Nicole Lyscom, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: +44 7791 866489
Email: nlyscom@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com